Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics' stock price has experienced significant volatility. As of November 25, 2025, the share price was $19.36, a substantial decline from $130.50 on November 26, 2024. Key events impacting the stock price include the FDA approval and label expansion for Elevidys, negative clinical updates and safety concerns, FDA restrictions and safety warnings for Elevidys, progress in the SRP-1003 study, and mixed analyst ratings.

Direct information explicitly detailing demand seasonality for Sarepta Therapeutics' products and services is not readily available. There might be observable seasonal patterns in the company's stock performance, which could indirectly reflect market expectations or other factors that might be influenced by seasonality. The nature of rare disease treatments might suggest less pronounced seasonality in patient demand compared to seasonal consumer goods.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in precision genetic medicines for rare diseases, particularly Duchenne muscular dystrophy (DMD). Sarepta operates within the biotechnology sector and the pharmaceuticals and healthcare industry, leveraging its Precision Genetic Medicine Engine, which includes gene therapy, RNA-targeted therapeutics, and gene editing. Its core business segments involve RNA-based therapies utilizing exon-skipping technology and gene therapy. Major approved products for the treatment of Duchenne muscular dystrophy include EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection, AMONDYS 45 (casimersen) Injection, and ELEVIDYS. Sarepta's pipeline includes approximately 40 programs at various stages of discovery, pre-clinical, and clinical development, addressing a range of diseases and disorders such as Duchenne, Limb-girdle muscular dystrophies (LGMDs), and other neuromuscular and central nervous system (CNS) related disorders.

Sarepta Therapeutics has a global presence with corporate offices and research facilities in Cambridge, Massachusetts, United States. The company also has international offices in Europe, specifically in Ireland, Switzerland, and the United Kingdom.

Sarepta Therapeutics' brand reputation has been influenced by its clinical trial outcomes and regulatory interactions, particularly concerning its Duchenne muscular dystrophy (DMD) therapies. Clinical setbacks and safety concerns, such as patient deaths and the FDA Boxed Warning for Elevidys, have negatively impacted its reputation. Positive clinical progress, such as the progress in the Phase 1/2 study of SRP-1003 for type 1 myotonic dystrophy (DM1) and the expanded label for Elevidys, have been viewed favorably.

Sarepta Therapeutics, Inc. is predominantly owned by institutional shareholders, who hold a significant portion of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and State Street Corp. Individual investors hold a smaller percentage of the stock. Black Bear Offshore Master Fund LP is noted as the largest individual shareholder.